ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

Metolazone

HCID 4170
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
17560-51-9
標準SMILES
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
InChIKey
AQCHWTWZEMGIFD-UHFFFAOYSA-N
分子式
C16H16ClN3O3S
平均分子量
365.8 g/mol
単同位体質量
365.0600902

概要

Metolazone is a quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. It has a role as a diuretic, an antihypertensive agent and an ion transport inhibitor. It is a sulfonamide, an organochlorine compound and a member of quinazolines.

名称と識別子

優先名称
Metolazone
IUPAC
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
英語名
metolazone
分子式
C16H16ClN3O3S
分子量
365.83

名称と別名

metolazone17560-51-9ZaroxolynDiuloMykroxOldrenMetenixMetalozoneMetolazonaMetolazonummetozaloneNormelan
名称をさらに表示
XuretSR 720-227-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamideSR-720-22Metazoline6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-DTXSID60451677-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide

データベース識別子

CAS
17560-51-9、56436-31-8、56436-32-9
PubChem CID
4170
DTXSID
DTXSID6045167
ChEMBL
CHEMBL878
ChEBI
CHEBI:64354
UNII
NM7V2Y3G0U、NN9U607695、TZ7V40X7VX
EC Number
241-539-3
Nikkaji
J3.450I

物性

構造計算による物性補完中

XLogP
4.1
極性表面積
101 Ų
水素結合供与体数
2
水素結合受容体数
5
回転可能結合数
2
重原子数
24
形式電荷
0
複雑度
594

実験および物理化学的性質

LogP · 2 件

2.5

1.8

OdorODORLESS
TasteTASTELESS
Color/FormCRYSTALS FROM ETHANOL
Solubility · 2 件

INSOL IN WATER & ALCOHOL

4.07e-02 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Thiazide Diuretics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 件

253-259 °C

256 °C

Physical DescriptionSolid
Stability/Shelf LifeLIGHT-SENSITIVE
Dissociation ConstantsPKA: 9.72
Collision Cross Section · 2 件

181.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

166.87 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental Properties · 3 件

ALSO REPORTED AS MP 246-250 °C (US PATENT 3,557,111)

PREVIOUSLY REPORTED AS POLYMORPHIC SOLID WITH MP RANGE 218-259 °C

TWO MAJOR POLYMORPHS ARE FORMED AS NOTED BY ENDOTHERMS @ ABOUT 227.5 °C & 276.5 °C

物理化学的性質

沸点
613.6 · 613.6±65.0 °C(Predicted)
比重(密度)
1.4 · 1.400±0.06 g/cm3(Predicted)
酸解離定数(Pka)
10 · 10.00±0.60(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

毒性情報

Interactions · 5 件

...METOLAZONE...CHEMICALLY & PHARMACOLOGICALLY RELATED TO THIAZIDE DIURETICS & ELEVATE SERUM URATE LEVELS. ...MAY...INTERACT WITH PROBENECID.

USE OF THIAZIDE DIURETIC MAY IMPAIR CONTROL OF DIABETES IN PT TREATED...WITH ORAL HYPOGLYCEMIC AGENTS OR INSULIN, BUT ONLY TO LIMITED EXTENT. /THIAZIDE DIURETICS/

METOLAZONE...STRUCTURALLY RELATED TO THIAZIDE DIURETICS, CAN CAUSE HYPOKALEMIA, & MAY BE EXPECTED TO INTERACT WITH CARDIAC GLYCOSIDES.

THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE... /THIAZIDE DIURETICS/

For more Interactions (Complete) data for METOLAZONE (6 total), please visit the HSDB record page.

Adverse Effects · 1 件

Hyperuricemia is a common adverse effect due to competitive inhibition of uric acid secretion and a decrease in extracellular fluid from diuretic effects. Other fluid and electrolyte imbalances may occur, especially hyponatremia, hypokalemia, and hypomagnesemia. Any electrolyte imbalances must be corrected before starting treatment. Metolazone may impair glucose tolerance, causing hyperglycemia and glycosuria. Diabetic patients should monitor their blood and urine glucose levels while on this therapy.

Toxicity Summary · 1 件

For diuretics in general, toxic doses are not well established. Chronic use is the most common cause of toxicity, such as hypotension and increased hematocrit due to plasma volume depletion and syncope. Hypokalemia, hyponatremia and reduced renal function, and increased mortality have been reported with the use of metolazone. Sodium levels should be corrected according to serum glucose levels.

Human Toxicity Excerpts · 2 件

ADVERSE EFFECTS... ANOREXIA, GASTRIC IRRITATION, NAUSEA, VOMITING, CRAMPING, DIARRHEA, JAUNDICE, PANCREATITIS, SIALADENITIS, DIZZINESS, VERTIGO, PARESTHESIAS, HEADACHE, XANTHOPSIA, LEUKOPENIA, AGRANULOCYTOSIS, THROMBOCYTOPENIA, APLASTIC ANEMIA, ORTHOSTATIC HYPOTENSION. /THIAZIDES/

ADVERSE EFFECTS... PURPURA, PHOTOSENSITIVITY, RASH, URTICARIA, NECROTIZING ANGITIS, FEVER, RESPIRATORY DISTRESS, ANAPHYLACTIC REACTIONS, HYPERGLYCEMIA, GLYCOSURIA, HYPERURICEMIA, MUSCLE SPASM, WEAKNESS, RESTLESSNESS, BLURRED VISION, & HEMATURIA. /THIAZIDES/

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Metolazone

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Non-Human Toxicity Values · 2 件

LD50 MICE ORAL MORE THAN 5000 MG/KG

LD50 MICE INTRAPERITONEAL MORE THAN 1500 MG/KG

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound
Pharmacodynamics · 1 件

Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

Mechanism of Action · 2 件

The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.

IT ACTS PRIMARILY TO INHIBIT SODIUM REABSORPTION AT CORTICAL DILUTING SITE & IN PROXIMAL CONVOLUTED TUBULE. SODIUM & CHLORIDE IONS ARE EXCRETED IN APPROX EQUAL AMT; INCR POTASSIUM EXCRETION MAY ALSO OCCUR. DIURETIC POTENCY APPROXIMATES THAT OF THIAZIDES.

Biological Half-Life · 3 件

Approximately 14 hours.

LONG T/2 VALUE...IN DOGS IS RELATED TO TRANSPORT MECHANISM IN BLOOD & PARTITION BETWEEN FORMED ELEMENTS & SERUM PROTEINS.

...METOLAZONE IS EXCRETED BY GLOMERULAR FILTRATION & TUBULAR SECRETION IN DOGS, ALTHOUGH DRUG:CREATININE CLEARANCE RATIO IS LOWER THAN FOR MOST OTHER DIURETICS. T/2 IN DOGS OF 5-6 HR IS INFLUENCED BY EXTENSIVE BINDING TO ERYTHROCYTES & PLASMA PROTEINS, & POSSIBLY TO TISSUE PROTEINS.

Metabolism/Metabolites · 2 件

Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling.

SEVENTY-FIVE PER CENT OF DOSE /ADMIN TO DOGS/ IS EXCRETED IN URINE & 25% IN BILE. 60%...AS HYDROXYLATED DERIV...& FURTHER PRODUCTS OF OXIDN...& UNIDENTIFIED POLAR METABOLITES ARE ALSO PRESENT IN URINE.

FDA Pharmacological Classification · 6 件

TZ7V40X7VX

METOLAZONE

Physiologic Effects [PE] - Increased Diuresis

Established Pharmacologic Class [EPC] - Thiazide-like Diuretic

Metolazone is a Thiazide-like Diuretic. The physiologic effect of metolazone is by means of Increased Diuresis.

METOLAZONE

MeSH Pharmacological Classification · 3 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that promote the excretion of urine through their effects on kidney function.

Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.

Absorption, Distribution and Excretion · 4 件

Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent.

Most of the drug is excreted in the unconverted form in the urine.

75% OF DOSE /ADMIN TO DOGS/ ...EXCRETED IN URINE & 25% IN BILE. 60%...AS HYDROXYLATED DERIV...& FURTHER PRODUCTS OF OXIDN...& UNIDENTIFIED POLAR METABOLITES ARE ALSO PRESENT IN URINE.

RENAL CLEARANCES OF.../THIAZIDE DIURETICS/ ARE...HIGH. MOST COMPOUNDS ARE RAPIDLY EXCRETED WITHIN 3-6 HR. BENDROFLUMETHIAZIDE & POLYTHIAZIDE HAVE LONGER DURATION OF ACTION THAT IS CORRELATED WITH SLOWER EXCRETION... SAME IS TRUE OF...METOLAZONE.

Cellular LocationsMembrane
Metabolite PathwaysMetolazone Action Pathway

用途と製造

UsesMEDICATION
Methods of Manufacturing · 2 件

SHETTY, US PATENTS 3,360,518 (1967 TO WALLACE & TIERNAN) AND 3,557,111 (1971); SHETTY ET AL, J MED CHEM 13, 886 (1970).

5-CHLORO-O-TOLUIDINE IS CONVERTED THROUGH SERIES OF REACTIONS INTO N-(O-TOLYL)-2-AMINO-4-CHLORO-5-SULFAMOYLBENZAMIDE WHICH IS CAUSED TO UNDERGO RING CLOSURE THROUGH REACTION WITH ACETALDEHYDE. US PATENT 3,360,518.

Formulations/PreparationsZAROXOLYN (PENNWALT), TABLETS 2.5, 5, & 10 MG.
Use ClassificationPharmaceuticals

関連反応

1 件
反応記録を作成
HRID 1781246 の反応式
HRID 1781246反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート